Revance Therapeutics (RVNC) Misses Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Revance Therapeutics (RVNC) Misses Q3 EPS by 8c

Revance Releases Third Quarter 2017 Results

November 2, 2017 4:05 PM EDT

-SAKURA 1 & 2 Phase 3 pivotal trials on track to report topline results before year-end 2017-

-SAKURA 3 open-label safety study for glabellar lines has completed enrollment of more than 2,100 subjects-

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced results for the third quarter ended September 30, 2017.

Recent Highlights and Upcoming Milestones for DaxibotulinumtoxinA for Injection (RT002)

Completed enrollment of more than 2,100 subjects at multiple... More